Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond
By H. Ghofrani, I. Osterloh, F. Grimminger. Nature reviews. Drug discovery, 2006
596 citations recorded by the source corpus.
In less than 20 years, the first selective type 5 phosphodiesterase inhibitor, sildenafil, has evolved from a potential anti-angina drug to an on-demand oral treatment for erectile dysfunction (Viagra), and more recently to a new orally active treatment for pulmonary hypertension (Revatio). Here we describe the key milestones in the development of sildenafil for these diverse medical conditions, discuss the advances in science and clinical medicine that have accompanied this journey and consider possible future indications for this versatile drug.
Subfields: Endocrinology, Diabetes and Metabolism, Psychiatry and Mental health, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/f66562a42d7b1da59b6d9f50a49dea3b3cd371e8
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- R. Schermuly
- F. Grimminger
- M. Wilkins
Citations in the corpus
- Mechanisms of disease: pulmonary arterial hypertension (2011, background): “12, 13 Reduced levels of the vasodilatory and antiproliferative nitric oxide (NO; generated via NO synthases), and cyclic guanosine monophosphate (the second messenger downstream of NO) are also well described in pulmonary vascular disease, including PAH. 14, 15 Increased levels of asymmetric dimeth”